NCT03871361View on ClinicalTrials.gov

Abatacept in Patients With Birdshot HLA A29 Uveitis

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

January 1, 2022

Study Completion Date

December 1, 2023

Conditions
Eye DiseasesUveitis
Interventions
DRUG

Abatacept 125 MG/ML Prefilled Syringe

Abatacept 125 MG/ML Prefilled Syringe \[Orencia\] weekly

Trial Locations (1)

3000

UZLeuven, Leuven

All Listed Sponsors
collaborator

Ziekenhuis Netwerk Antwerpen (ZNA)

OTHER

lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT03871361 - Abatacept in Patients With Birdshot HLA A29 Uveitis | Biotech Hunter | Biotech Hunter